Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation

Summary

ARO-DECAMP is a multi-centre, placebo-controlled, pilot and feasibility randomized controlled trial for the microbial consortium Microbial Ecosystem Therapeutic-2. Non-intensive care unit patients ≥ 18 years old diagnosed with a bloodstream infection and receiving treatment for an antibiotic resistant organism will be included. Participants will be randomized to receive either MET-2 or placebo for 10 days. Recruitment rate and study intervention adherence will be evaluated for feasibility. Participants will be followed for 180 days, and biological samples will be collected periodically for clinical, ecological, and biomarker outcomes.

Timeline

Start

2026-07

Primary completion

2028-01

Completion

2028-07

Outcome

Outcome not reported

Stopped: “Study intervention not available. Manufacturer no longer producing MET-2.”

Drugs

Indications